Analysis Targeted Medical Pharma, Inc. (TRGM)
5/28/2024
Analysis of Targeted Medical Pharma, Inc. (TRGM)
Based on the provided data for Targeted Medical Pharma, Inc. (symbol: TRGM), we can see that the stock price has remained constant at $0.00010 for the past several days. The technical indicators such as RSI, MACD, and moving averages (SMA, EMA, WMA) are also showing no significant changes or signals.Given the lack of movement in the stock price and technical indicators, it appears that TRGM is currently experiencing a period of consolidation or low volatility. Investors may want to monitor the stock for any potential breakout or trend reversal in the future before making any trading decisions.
Please note that this analysis is based on the provided data and a more comprehensive analysis would require additional information and market context.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating good financial performance. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows a solid return on assets and return on equity.
Stock statistics show details such as short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. The company's stock price summary includes beta, moving averages, and the fifty-two week low and high prices.
Valuation metrics reveal information about the company's price-to-earnings ratios, enterprise value, price-to-book ratio, price-to-sales ratio, and market capitalization.
Lastly, dividends and splits data include details about dividend rates, payout ratios, dividend dates, and historical split information.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management strategies.
3. The gross profit margin has remained relatively stable over the years, hovering around 44% to 45%.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, indicating efficient operational performance.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets, resulting in a growth in shareholders' equity.
5. Shareholders' equity includes common stock, retained earnings, and other equity components.
6. The company has been managing its short-term and long-term debts while investing in assets for future growth.
7. Accumulated depreciation is significant and has been increasing over the years, affecting the value of non-current assets.
8. The company has been maintaining a healthy balance between current and non-current assets and liabilities.
9. Overall, the financial position of the company seems stable and shows a positive trend in terms of asset growth and equity.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variations, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with notable amounts spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities seem to be dynamic, with varying cash flows from different sources.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.33
- Low Estimate: $1.27
- High Estimate: $1.36
- Year Ago EPS: $1.26
- Number of Analysts: 26
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.53
- Low Estimate: $1.44
- High Estimate: $1.63
- Year Ago EPS: $1.46
- Number of Analysts: 25
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.59
- Low Estimate: $6.43
- High Estimate: $6.92
- Year Ago EPS: $6.13
- Number of Analysts: 39
4. Next Year (as of September 30, 2025):
- Average Estimate: $7.23
- Low Estimate: $6.40
- High Estimate: $7.90
- Year Ago EPS: $6.59
- Number of Analysts: 39
Based on these estimates, we can see a generally positive trend in the expected earnings per share for both the upcoming quarters and the next two years. The average estimates are showing an increase compared to the year-ago EPS figures, indicating potential growth in earnings for the company.
Revenue estimate
Based on analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year and 9.7% in the next year.
- For the current quarter, the growth rate is estimated to be 5.6%, while for the next quarter it is projected to be 4.8%.
- Over the next 5 years, the company is expected to achieve an average annual growth rate of 11%.
- However, in the past 5 years, the company has experienced a higher average annual growth rate of approximately 20.1%.
Overall, the company is expected to maintain a positive growth trajectory, with a slightly lower growth rate in the short term compared to the long-term average.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is below both the average and median forecast, indicating a potential upside according to the analysts' predictions.
MACD of TRGM
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
